# Context Therapeutics (CNTX) — News

CNTX · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/cntx/news

## Recent headlines

- [Context Therapeutics announces first patient dosed in phase 1 trial of CT-202](https://www.ainvest.com/news/context-therapeutics-announces-patient-dosed-phase-1-trial-ct-202-2609) — AInvest Wire, Sep 9, 2026
- [Context Therapeutics Inc. Q2 basic EPS USD -0.15](https://www.ainvest.com/news/context-therapeutics-q2-basic-eps-usd-0-15-2608) — AInvest Wire, Aug 5, 2026
- [Context Therapeutics Inc. Q2 net income USD -14.6 million](https://www.ainvest.com/news/context-therapeutics-q2-net-income-usd-14-6-million-2608) — AInvest Wire, Aug 5, 2026
- [Context Therapeutics announces inducement grant under Nasdaq listing Rule 5635(c)(4)](https://www.ainvest.com/news/context-therapeutics-announces-inducement-grant-nasdaq-listing-rule-5635-4-2606) — AInvest Wire, Jun 9, 2026
- [CnTx pact provides economic rights to CT-202 going forward](https://www.ainvest.com/news/cntx-pact-economic-rights-ct-202-2605) — AInvest Wire, May 18, 2026
  Context Therapeutics Inc. (Nasdaq: CNTX) has secured economic rights to its investigational bispecific T cell engaging (TCE) antibody, CT-202, moving forward. CT-202 is a Nectin-4 x CD3 TCE bispecific antibody designed to target Nectin-4, a cell surface protein overexpressed in various solid…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).